CDMOs offering Sterile Fill-Finish & Aseptic Manufacturing with mRNA

Matching companies

• AGC Biologics

  Global CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.

• Aldevron

  Aldevron is a CDMO specializing in mRNA manufacturing with LNP encapsulation and fill/finish, viral vector production, plasmid DNA, and gene therapy solutions from discovery through commercialization.

• Biomay AG

  GMP CDMO specializing in plasmid DNA, mRNA, and recombinant protein manufacturing from gene construction to market supply, with in-house mRNA lipid-nanoparticle formulation and aseptic fill-finish capabilities.

• CordenPharma

  Full-service CDMO offering cGMP development and manufacturing of APIs, lipid excipients, drug products, injectables, peptides, LNPs, oligonucleotides, and oral solid dose across 10 facilities in 6 countries with 3000+ employees.

• Curia

  Global CDMO with 30+ years of experience offering integrated services across small molecule, generic APIs, sterile drug product, and biologics manufacturing, backed by 20+ facilities and 3,000+ professionals across North America, Europe, and India.

• Fujifilm Pharmaceuticals U.S.A., Inc

  CDMO specializing in liposome and lipid nanoparticle (LNP) formulation development and GMP manufacturing from bench to commercial scale, with mRNA process development and aseptic fill-finish capabilities.

• Hongene Biotech Corporation

  Hongene is a vertically-integrated CDMO offering end-to-end oligonucleotide and mRNA manufacturing from raw materials to GMP drug product, with nearly 30 years of RNA-focused expertise and tonne-scale production capacity.

• National Resilience

  End-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.

• Patheon (Thermo Fisher Pharma Services)

  Patheon is a trusted global contract development and manufacturing organization (CDMO) partner owned by Thermo Fisher Scientific, offering 360° integrated solutions from early-stage R&D through clinical supply and commercial manufacturing.

• Pharmaron

  Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.

• Porton Advanced

  End-to-end ATMP CDMO provider offering cell engineering, lentiviral vectors, mRNA/LNP, plasmid development, and GMP manufacturing from preclinical through commercialization with 24 IND approvals across NMPA, FDA, and MedSafe.

• Samsung Biologics

  Leading CDMO offering end-to-end biologics development and manufacturing from cell line development through aseptic fill-finish, with capabilities in drug substance, drug product, ADC, and mRNA services.

• Sophia CDMO

  European CDMO specializing in microbial and precision fermentation up to 40,000 L across two integrated sites (Pamplona, Spain and Basel, Switzerland), with core strengths in E. coli expression, animal health biologics, probiotics, and complex CMC programs requiring scale-up discipline and impurity control.

• Stevanato Group

  Leading global provider of integrated drug containment, drug delivery, and diagnostic solutions with 75+ years' experience in glass primary packaging, contract manufacturing, and analytical services across development, clinical, and commercial stages.

• Syngene International

  Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.

• eXmoor Pharma

  Integrated cell and gene therapy CDMO with 20+ years of consultancy expertise, offering end-to-end CMC support from early-phase strategy through GMP manufacturing across viral vectors, autologous/allogeneic cell therapies, and RNA technologies.